NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC

This trial confirms benefit of adding neoadjuvant nivolumab to chemotherapy in patients with resectable stage IIIA/B NSCLC, with a pCR rate of 36.8% vs 6.9% with neoadjuvant chemotherapy alone and no impediment to definitive surgery.